NASDAQ:NYXH

Nyxoah - NYXH Stock Forecast, Price & News

$5.11

-0.09 (-1.73%)

(As of 12/1/2022 12:00 AM ET)

Add

Compare

Today's Range: $5.08
▼
$5.41
50-Day Range: $5.11
▼
$6.39
52-Week Range: $5.07
▼
$23.05

Volume: 24,891 shs
Average Volume: 4,311 shs
Market Capitalization: $127.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.33

Nyxoah MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 317.5% Upside
$21.33 Price Target
Short Interest: Healthy
0.02% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.58
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.02) to ($1.61) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

370th out of 1,052 stocks

Surgical & Medical Instruments Industry

39th out of 104 stocks

3.4

Analyst's Opinion

Consensus Rating
Nyxoah has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.33, Nyxoah has a forecasted upside of 317.5% from its current price of $5.11.
Amount of Analyst Coverage
Nyxoah has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.02% of the float of Nyxoah has been sold short.
Short Interest Ratio / Days to Cover
Nyxoah has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Nyxoah has recently decreased by 32.00%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Nyxoah does not currently pay a dividend.
Dividend Growth
Nyxoah does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NYXH.

4.2

News and Social Media Coverage

News Sentiment
Nyxoah has a news sentiment score of 1.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Nyxoah this week, compared to 0 articles on an average week.
Search Interest
1 people have searched for NYXH on MarketBeat in the last 30 days.
MarketBeat Follows
2 people have added Nyxoah to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nyxoah insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 12.07% of the stock of Nyxoah is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Nyxoah are expected to decrease in the coming year, from ($1.02) to ($1.61) per share.
Price to Book Value per Share Ratio
Nyxoah has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Nyxoah (NASDAQ:NYXH) Stock

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Receive NYXH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nyxoah and its competitors with MarketBeat's FREE daily newsletter.

NYXH Stock News Headlines

November 17, 2022 | finance.yahoo.com

Nyxoah to Participate in the Piper Sandler 34th Annual Healthcare Conference

November 16, 2022 | finance.yahoo.com

Wall Street Analysts See a 240% Upside in Nyxoah SA (NYXH): Can the Stock Really Move This High?

November 8, 2022 | finance.yahoo.com

Nyxoah Reports Third Quarter 2022 Financial and Operating Results

October 25, 2022 | finance.yahoo.com

Nyxoah Announces Change to Board of Directors

October 20, 2022 | finance.yahoo.com

Nyxoah to Participate in the Jefferies London Healthcare Conference

October 18, 2022 | finance.yahoo.com

Nyxoah to Release Third Quarter Financial Results on November 8, 2022

August 13, 2022 | seekingalpha.com

Nyxoah S.A. (NYXH) CEO Olivier Taelman on Q2 2022 Results - Earnings Call Transcript

August 11, 2022 | finance.yahoo.com

Wall Street Analysts Believe Nyxoah SA (NYXH) Could Rally 170%: Here's is How to Trade

August 8, 2022 | finance.yahoo.com

Nyxoah S.A. (NYXH) Q2 2022 Earnings Call Transcript

August 8, 2022 | finance.yahoo.com

Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating Results

August 2, 2022 | finance.yahoo.com

Nyxoah and Acurable Enter into Distribution Agreement in Germany for the AcuPebble SA100 Home Sleep Test

July 27, 2022 | finance.yahoo.com

Nyxoah to Present at the Canaccord Genuity 42nd Annual Growth Conference

July 19, 2022 | finance.yahoo.com

Nyxoah to Release Second Quarter and First Half 2022 Financial Results on August 8, 2022

July 19, 2022 | finance.yahoo.com

Nyxoah Secures European Approval For Genio 2.1 Neurostimulation Therapy For Sleep Apnea

July 12, 2022 | finance.yahoo.com

Nyxoah SA (NYXH) Stock Jumps 13.2%: Will It Continue to Soar?

July 11, 2022 | finance.yahoo.com

FDA Signs Off Nyxoah's Genio Trial In Complete Concentric Collapse Patients

June 7, 2022 | finance.yahoo.com

Nyxoah Joins the Euronext Tech Leaders Initiative, Included in the Euronext Tech Leaders Index

June 3, 2022 | finanznachrichten.de

Nyxoah: FDA Approves Genio 2.1 For Use in DREAM U.S. IDE Pivotal Study

June 1, 2022 | finance.yahoo.com

FDA Approves Genio® 2.1 For Use in DREAM U.S. IDE Pivotal Study

May 11, 2022 | nasdaq.com

Nyxoah S.A. (NYXH) Q1 2022 Earnings Call Transcript

May 9, 2022 | finance.yahoo.com

Nyxoah Reports First Quarter 2022 Financial and Operating Results

April 28, 2022 | finance.yahoo.com

Nyxoah to Release First Quarter 2022 Financial Results on May 9 and Host Conference Call on May 10, 2022

March 25, 2022 | fool.com

Nyxoah S.A. (NYXH) Q4 2021 Earnings Call Transcript

March 14, 2022 | benzinga.com

BETTER SLEEP Achieves Primary Endpoint Across All Patient Cohorts

March 10, 2022 | finance.yahoo.com

Nyxoah to Participate in the Oppenheimer 32nd Annual Healthcare Conference

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NYXH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nyxoah and its competitors with MarketBeat's FREE daily newsletter.

NYXH Company Calendar

Last Earnings: 11/08/2022
Today: 12/02/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/23/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NYXH
CUSIP: N/A
CIK: 1857190
Web: www.nyxoah.com
Phone: 321-022-2355
Fax: 321-045-9075
Employees: 105
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $21.33
High Stock Price Forecast: $30.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +317.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.08
Current Ratio: 5.97
Quick Ratio: 5.94

Sales & Book Value

Annual Sales: $1.01 million
Price / Sales: 126.18
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.37 per share
Price / Book: 0.95

Miscellaneous

Outstanding Shares: 24,940,000
Free Float: N/A
Market Cap: $127.44 million
Optionable: Not Optionable
Beta: 1.16

Key Executives

Mr. Robert Taub MBA (Age 75)
Co-Founder & Chairman
Comp: $63.53k

Mr. Olivier Taelman (Age 50)
CEO & Exec. Director
Comp: $753.11k

Mr. Loic Moreau (Age 42)
Chief Financial Officer

Ms. Dorit Nahari
VP of Operations

Mr. Bruno Onkelinx
Chief Technology Officer

Mr. Jeremy Feffer
VP of Investor Relations & Corp. Communication

Ms. An Moonen
Gen. Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NYXH Stock - Frequently Asked Questions

Should I buy or sell Nyxoah stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nyxoah in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NYXH shares.
View NYXH analyst ratings or view top-rated stocks.
What is Nyxoah's stock price forecast for 2023?: 4 equities research analysts have issued 1-year price objectives for Nyxoah's shares. Their NYXH share price forecasts range from $13.00 to $30.00. On average, they expect the company's share price to reach $21.33 in the next twelve months. This suggests a possible upside of 317.5% from the stock's current price.
View analysts price targets for NYXH or view top-rated stocks among Wall Street analysts.
How have NYXH shares performed in 2022?: Nyxoah's stock was trading at $23.00 at the start of the year. Since then, NYXH stock has decreased by 77.8% and is now trading at $5.11.
View the best growth stocks for 2022 here.
Are investors shorting Nyxoah?: Nyxoah saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 1,700 shares, a drop of 32.0% from the October 31st total of 2,500 shares. Based on an average daily volume of 3,400 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.0% of the shares of the company are short sold.
View Nyxoah's Short Interest.
When is Nyxoah's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our NYXH earnings forecast.
How were Nyxoah's earnings last quarter?: Nyxoah S.A. (NASDAQ:NYXH) issued its quarterly earnings data on Tuesday, November, 8th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.06. The company had revenue of $0.18 million for the quarter, compared to analysts' expectations of $1.40 million.

When did Nyxoah IPO?: (NYXH) raised $83 million in an initial public offering (IPO) on Friday, July 2nd 2021. The company issued 2,760,000 shares at a price of $30.00 per share.
What is Nyxoah's stock symbol?: Nyxoah trades on the NASDAQ under the ticker symbol "NYXH."
Who are Nyxoah's major shareholders?: Nyxoah's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.62%), AXA S.A. (0.80%) and Banque Cantonale Vaudoise (0.12%).
How do I buy shares of Nyxoah?: Shares of NYXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Nyxoah's stock price today?: One share of NYXH stock can currently be purchased for approximately $5.11.
How much money does Nyxoah make?: Nyxoah (NASDAQ:NYXH) has a market capitalization of $127.44 million and generates $1.01 million in revenue each year.
How many employees does Nyxoah have?: The company employs 105 workers across the globe.
How can I contact Nyxoah?: The official website for the company is www.nyxoah.com. The company can be reached via phone at 321-022-2355, via email at ir@nyxoah.com, or via fax at 321-045-9075.

This page (NASDAQ:NYXH) was last updated on 12/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial